BR0307595A - Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico - Google Patents

Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico

Info

Publication number
BR0307595A
BR0307595A BR0307595-8A BR0307595A BR0307595A BR 0307595 A BR0307595 A BR 0307595A BR 0307595 A BR0307595 A BR 0307595A BR 0307595 A BR0307595 A BR 0307595A
Authority
BR
Brazil
Prior art keywords
sildenafil
treatment
pde5 inhibitors
polycystic ovarian
ovarian syndrome
Prior art date
Application number
BR0307595-8A
Other languages
English (en)
Inventor
Mahmoud Nizar Ghazzi
Nandan Parmanand Koppiker
Simon Lempriere Westbrook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307595A publication Critical patent/BR0307595A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE INIBIDORES DE PDE5 TAL COMO SILDENAFIL NO TRATAMENTO DE SìNDROME DE OVáRIO POLICìSTICO". A presente invenção refere-se ao uso de um inibidor de PDE5 de pirazolopirimidinona tal como sildenafil para o tratamento de síndrome do ovário policístico.
BR0307595-8A 2002-02-07 2003-01-27 Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico BR0307595A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35503802P 2002-02-07 2002-02-07
PCT/IB2003/000257 WO2003066061A1 (en) 2002-02-07 2003-01-27 Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome

Publications (1)

Publication Number Publication Date
BR0307595A true BR0307595A (pt) 2005-02-01

Family

ID=27734455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307595-8A BR0307595A (pt) 2002-02-07 2003-01-27 Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico

Country Status (9)

Country Link
US (1) US20040029891A1 (pt)
EP (1) EP1471917A1 (pt)
JP (1) JP2005519927A (pt)
AU (1) AU2003205926A1 (pt)
BR (1) BR0307595A (pt)
CA (1) CA2475377A1 (pt)
MX (1) MXPA04007713A (pt)
TW (1) TW200303747A (pt)
WO (1) WO2003066061A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003256988A1 (en) * 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
EA200501548A1 (ru) * 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
ES2284081T3 (es) * 2003-12-19 2007-11-01 Bristol-Myers Squibb Company Heterociclos azabiciclicos como modulares de receptores canabinoides.
ZA200706020B (en) * 2005-01-10 2008-12-31 Cortendo Invest Ab Publ Methods and compositions for treating diabetes, metabolic syndrome and other conditions
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
WO2007081980A2 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer
AU2006341342B2 (en) * 2006-04-04 2010-05-20 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
CA2664800A1 (en) * 2006-10-02 2008-04-10 Timothy Andrew Stewart Ketoconazole enantiomer in humans
KR20100050488A (ko) * 2007-06-26 2010-05-13 솔베이 파마슈티칼스 비. 브이 전구약물로서 실데나필 ｎ-옥사이드
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
AU2011231285A1 (en) * 2010-03-22 2012-09-06 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a pyrimidineone derivative
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
CN106442764B (zh) * 2016-08-31 2019-01-22 王义明 多囊卵巢综合征的诊断和/或分型标志物及制备试剂的用途
WO2020172348A1 (en) * 2019-02-20 2020-08-27 Virginia Commonwealth University Methods for diagnosis and/or therapy of disorders that correlate with dennd1a variant 2
US11376263B2 (en) * 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof
DE202022104150U1 (de) 2022-07-22 2022-08-11 Malti Arya Eine polypharmazeutische Formulierung als potenzielles Mittel zur Behandlung des polyzystischen Ovarsyndroms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229510T3 (es) * 1997-06-27 2005-04-16 Fujisawa Pharmaceutical Co., Ltd. Derivados de anillo aromatico.
WO2000028991A1 (en) * 1998-11-13 2000-05-25 Fujisawa Pharmaceutical Co., Ltd. Remedies for polycystic ovary syndrome
AU2001276607A1 (en) * 2000-08-11 2002-02-25 Pfizer Inc. Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals

Also Published As

Publication number Publication date
CA2475377A1 (en) 2003-08-14
US20040029891A1 (en) 2004-02-12
EP1471917A1 (en) 2004-11-03
MXPA04007713A (es) 2004-11-10
TW200303747A (en) 2003-09-16
JP2005519927A (ja) 2005-07-07
AU2003205926A1 (en) 2003-09-02
WO2003066061A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
IL163781A0 (en) Purine derivatives as kinase inhibitors
MXPA04008613A (es) N-aminoacetil-pirrolidina-2-carbonitrilos y su uso como inhibidores de ddp-iv.
TW200720271A (en) DNA-PK inhibitors
GEP20105081B (en) Pyrrolotriazine compounds as kinase inhibitors
DE60314623D1 (de) Substituierte pyrazolopyrimidine
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
JO3795B1 (ar) تركيبة تشمل ميتفورمين وفيلداجلبتين
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
BRPI0507312A (pt) derivados de quinolina para uso como inibidores micobacterianos
ATE477256T1 (de) Thienylverbindungen
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
AU2003205926A1 (en) Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
BRPI0516555A (pt) processo de revestimento
BG108245A (en) Compositions containing imidazotriazinone for nasal application
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
WO2007120333A3 (en) Tetracyclic kinase inhibitors
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
MXPA06000372A (es) Compuestos de silicio y su uso.
EP1605926A4 (en) USE OF PINITOL OR CHIROINOSITOL FOR THE PROTECTION OF THE LIVER
BRPI0417263A (pt) imidazopiridinas para uso como inibidores de secreção gástrica
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
ATE396177T1 (de) Neue kristalline formen eines faktor xa inhibitors

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.